DK451388D0 - Terapeutisk nucleosider og farmaceutiske kompositioner indeholdende forbindelserne - Google Patents

Terapeutisk nucleosider og farmaceutiske kompositioner indeholdende forbindelserne

Info

Publication number
DK451388D0
DK451388D0 DK451388A DK451388A DK451388D0 DK 451388 D0 DK451388 D0 DK 451388D0 DK 451388 A DK451388 A DK 451388A DK 451388 A DK451388 A DK 451388A DK 451388 D0 DK451388 D0 DK 451388D0
Authority
DK
Denmark
Prior art keywords
compounds
pharmaceutical compositions
compositions containing
therapeutic nucleosides
nucleosides
Prior art date
Application number
DK451388A
Other languages
English (en)
Other versions
DK170045B1 (da
DK451388A (da
Inventor
Thomas Anthony Krenitsky
Lilia Marie Beauchamp
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26292613&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK451388(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB878719367A external-priority patent/GB8719367D0/en
Priority claimed from GB878725939A external-priority patent/GB8725939D0/en
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of DK451388D0 publication Critical patent/DK451388D0/da
Publication of DK451388A publication Critical patent/DK451388A/da
Application granted granted Critical
Publication of DK170045B1 publication Critical patent/DK170045B1/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
DK451388A 1987-08-15 1988-08-12 2-((2-Amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy)ethyl-L-valinat og salte heraf, disse forbindelsers anvendelse inden for medicinsk terapi, farmaceutisk komposition indeholdende en sådan forbindelse, samt fremgangsmåde til fremstilling af forbindelserne DK170045B1 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB878719367A GB8719367D0 (en) 1987-08-15 1987-08-15 Therapeutic compounds
GB8719367 1987-11-05
GB8725939 1987-11-05
GB878725939A GB8725939D0 (en) 1987-11-05 1987-11-05 Therapeutic compounds

Publications (3)

Publication Number Publication Date
DK451388D0 true DK451388D0 (da) 1988-08-12
DK451388A DK451388A (da) 1989-02-16
DK170045B1 DK170045B1 (da) 1995-05-08

Family

ID=26292613

Family Applications (2)

Application Number Title Priority Date Filing Date
DK451388A DK170045B1 (da) 1987-08-15 1988-08-12 2-((2-Amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy)ethyl-L-valinat og salte heraf, disse forbindelsers anvendelse inden for medicinsk terapi, farmaceutisk komposition indeholdende en sådan forbindelse, samt fremgangsmåde til fremstilling af forbindelserne
DK082694A DK170803B1 (da) 1987-08-15 1994-07-08 2-((2-Amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy)-ethyl-L-isoleucinat og salte heraf, disse forbindelsers anvendelse inden for medicinsk terapi, og farmaceutisk komposition indeholdende en sådan forbindelse

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK082694A DK170803B1 (da) 1987-08-15 1994-07-08 2-((2-Amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy)-ethyl-L-isoleucinat og salte heraf, disse forbindelsers anvendelse inden for medicinsk terapi, og farmaceutisk komposition indeholdende en sådan forbindelse

Country Status (30)

Country Link
EP (2) EP0308065B1 (da)
JP (2) JPH0662623B2 (da)
KR (2) KR960002849B1 (da)
CN (1) CN1033701C (da)
AP (2) AP55A (da)
AT (1) ATE138660T1 (da)
AU (1) AU612393C (da)
CS (1) CS276903B6 (da)
CY (1) CY1833A (da)
DE (1) DE3855333T2 (da)
DK (2) DK170045B1 (da)
ES (1) ES2087639T3 (da)
FI (1) FI89713C (da)
GR (1) GR3020372T3 (da)
HU (1) HU201071B (da)
IE (1) IE65551B1 (da)
IL (1) IL87434A (da)
LU (1) LU88746I2 (da)
LV (1) LV5264A3 (da)
MC (1) MC1968A1 (da)
MX (1) MX9203418A (da)
MY (1) MY103760A (da)
NL (1) NL960001I2 (da)
NO (2) NO167805C (da)
NZ (1) NZ225809A (da)
PL (1) PL158285B1 (da)
PT (1) PT88261B (da)
SA (1) SA95160244B1 (da)
SG (1) SG26346G (da)
SU (1) SU1634138A3 (da)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP55A (en) * 1987-08-15 1989-09-26 The Wellcome Foundation Ltd Therapeutic Acyclic Nucleosides
GB8816760D0 (en) * 1988-07-14 1988-08-17 Wellcome Found Therapeutic compounds
GB8829571D0 (en) * 1988-12-19 1989-02-08 Wellcome Found Antiviral compounds
CA2005815C (en) * 1988-12-19 1999-08-03 Wellcome Foundation Limited (The) Antiviral acyclic nucleoside derivatives
DE4008858A1 (de) * 1990-03-20 1991-09-26 Hoechst Ag Substituierte purine, verfahren zu ihrer hertellung sowie ihre verwendung als antivirale mittel
EP0702682B1 (en) * 1993-06-10 2001-03-14 Rolabo Sl Process for the preparation of amino acid esters of nucleoside analogues
GB9317146D0 (en) * 1993-08-18 1993-10-06 Wellcome Found Therapeutic combinations
GB9320316D0 (en) * 1993-10-01 1993-11-17 Smithkline Beecham Plc Pharmaceuticals
TW282470B (da) * 1993-11-18 1996-08-01 Ajinomoto Kk
DE69513313T2 (de) * 1994-02-01 2000-07-13 Ajinomoto Co., Inc. Verfahren zur Herstellung von Nukleinsäurebasenderivaten
PE32296A1 (es) * 1994-07-28 1996-08-07 Hoffmann La Roche Ester de l-monovalina derivado de 2-(2-amino-1,6-dihidro-6-oxo-purin-9-il) metoxi-1,3-propandiol y sus sales farmaceuticamente aceptables
US5543414A (en) * 1994-07-28 1996-08-06 Syntex (Usa) Inc. Achiral amino acid acyl esters of ganciclovir and its derivatives
US5840891A (en) * 1994-07-28 1998-11-24 Syntex (U.S.A.) Inc. 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3-propanediol derivative
GB9501178D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Guanine derivative
GB9501127D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Tablet
GB9501142D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Compounds for use in medicine
DE19536164A1 (de) * 1995-09-28 1997-04-03 Boehringer Ingelheim Kg Verbessertes Verfahren zur Herstellung von 9-[(2-Hyroxyethoxy)methyl]guanin (Acyclovir)
CA2243237C (en) * 1996-01-19 2008-09-02 Glaxo Group Limited Use of valaciclovir for the manufacture of a medicament for the treatment of genital herpes by a single daily application
US5756736A (en) * 1996-01-26 1998-05-26 Syntex (U.S.A.) Inc. Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative
CN1064683C (zh) * 1996-01-26 2001-04-18 弗·哈夫曼-拉罗切有限公司 制备嘌呤衍生物的方法
US6040446A (en) * 1996-01-26 2000-03-21 Syntex (U.S.A.) Inc. Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3-propanediol derivative
US5840890A (en) * 1996-01-26 1998-11-24 Syntex (U.S.A.) Inc. Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative
US5700936A (en) * 1996-01-26 1997-12-23 Syntex (U.S.A.) Inc. Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3-propanediol valinate
US5869493A (en) * 1996-02-16 1999-02-09 Medivir Ab Acyclic nucleoside derivatives
US6703394B2 (en) 1996-02-16 2004-03-09 Medivir Ab Acyclic nucleoside derivatives
IT1283447B1 (it) * 1996-07-18 1998-04-21 Ind Chimica Srl Processo di preparazione del valaciclovir e relativi intermedi
KR20000070223A (ko) * 1997-01-17 2000-11-25 에가시라 구니오 신규한 ｚ-발라사이클로비르 결정
CA2332961A1 (en) * 1998-05-21 1999-11-25 Michael Zasloff A method for stimulation of defensin production by exposure to isoleucine
WO2003022209A2 (en) * 2001-09-07 2003-03-20 Teva Pharmaceutical Industries Ltd. Crystalline forms of valacyclovir hydrochloride
WO2004000265A2 (en) 2002-06-24 2003-12-31 Ranbaxy Laboratories Limited Process for the preparation of robust formulations of valacyclovir hydrochloride tablets
US20050043329A1 (en) * 2002-09-06 2005-02-24 Shlomit Wizel Crystalline forms of valacyclovir hydrochloride
CN1309732C (zh) * 2002-10-28 2007-04-11 南京长澳医药科技有限公司 6－烷氧基－2’，3’－双脱氧鸟嘌呤核苷的制备方法
CA2527708A1 (en) * 2003-06-02 2005-01-06 Teva Pharmaceutical Industries Ltd. Crystalline forms of valacyclovir hydrochloride
CN1331471C (zh) * 2003-09-22 2007-08-15 陈云芳 盐酸万乃洛韦软胶囊组合物
MXPA06008197A (es) * 2004-01-21 2007-04-02 Teva Pharma Proceso para la preparacion de clorhidrato de valaciclovir.
GB2413017A (en) * 2004-04-06 2005-10-12 Ford Global Tech Llc An electrical connector for a vehicle
WO2006035452A1 (en) * 2004-09-27 2006-04-06 Matrix Laboratories Ltd Novel pseudomorph of valaciclovir hydrochloride
EP1891071B1 (en) 2005-05-25 2012-02-22 Eli Lilly And Company Cyclopropanecarboxylate esters of acyclovir
EP1746098A1 (en) 2005-07-21 2007-01-24 SOLMAG S.p.A. Valacyclovir polymorphs and a process for the preparation thereof
CN101456859B (zh) * 2009-01-06 2011-07-20 华南理工大学 抗病毒药物缬昔洛韦的制备方法
WO2011158252A1 (en) 2010-06-15 2011-12-22 Matrix Laboratories Ltd Process for the preparation of valacyclovir hydrochloride polymorphic form ii
CN102850354B (zh) * 2012-10-10 2014-07-23 山东金城医药化工股份有限公司 高纯度cbz-万乃洛韦的制备方法
CN106632335A (zh) * 2016-12-27 2017-05-10 河南康达制药有限公司 一种盐酸伐昔洛韦的制备方法
RU2750867C1 (ru) * 2020-05-18 2021-07-05 Александр Сергеевич Самойлов Производные гуанина

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8202626A (nl) * 1982-06-29 1984-01-16 Stichting Rega V Z W Derivaten van 9-(2-hydroxyethoxymethyl)guanine.
DE3627024A1 (de) * 1985-09-24 1987-04-02 Hoechst Ag In 6- und 9-stellung substituierte 2-aminopurine, ihre verwendung, diese purine enthaltende arzneimittel und verfahren zur herstellung der purine
DE3534774A1 (de) * 1985-09-30 1987-04-02 Robugen Gmbh Nucleosid-analoge verbindungen mit antiviraler aktivitaet, verfahren zu deren herstellung sowie arzneimittel mit antiviraler wirkung
AP55A (en) * 1987-08-15 1989-09-26 The Wellcome Foundation Ltd Therapeutic Acyclic Nucleosides

Also Published As

Publication number Publication date
KR960002849B1 (ko) 1996-02-27
CN1032538A (zh) 1989-04-26
JPS6468373A (en) 1989-03-14
DK170045B1 (da) 1995-05-08
FI883757A0 (fi) 1988-08-12
NZ225809A (en) 1991-07-26
AU2097888A (en) 1989-02-16
DK170803B1 (da) 1996-01-22
MC1968A1 (fr) 1989-09-29
EP0308065B1 (en) 1995-01-04
NO883612D0 (no) 1988-08-12
EP0596542A1 (en) 1994-05-11
AU612393B2 (en) 1991-07-11
MY103760A (en) 1993-09-30
AP160A (en) 1991-11-18
NO167805B (no) 1991-09-02
GR3020372T3 (en) 1996-09-30
IE65551B1 (en) 1995-11-01
KR960004940B1 (ko) 1996-04-18
FI89713C (fi) 1993-11-10
PL274215A1 (en) 1990-02-19
HU201071B (en) 1990-09-28
CY1833A (en) 1995-12-01
PT88261B (pt) 1995-03-01
NO167805C (no) 1991-12-11
CS276903B6 (en) 1992-09-16
CN1033701C (zh) 1997-01-01
MX9203418A (es) 1992-07-01
JPH03115284A (ja) 1991-05-16
DE3855333T2 (de) 1996-12-05
SU1634138A3 (ru) 1991-03-07
IL87434A0 (en) 1989-01-31
NO1996015I1 (no) 1996-12-17
DK451388A (da) 1989-02-16
ATE138660T1 (de) 1996-06-15
FI883757A (fi) 1989-02-16
EP0308065A3 (en) 1989-09-27
KR890003761A (ko) 1989-04-17
CS8805594A2 (en) 1990-06-13
ES2087639T3 (es) 1996-07-16
AP8800099A0 (en) 1988-08-01
FI89713B (fi) 1993-07-30
PL158285B1 (en) 1992-08-31
SG26346G (en) 1995-09-01
EP0596542B1 (en) 1996-05-29
IE882463L (en) 1989-02-15
IL87434A (en) 1993-06-10
AU612393C (en) 2006-08-17
PT88261A (pt) 1989-06-30
NL960001I2 (nl) 1996-11-01
LU88746I2 (fr) 1996-10-04
SA95160244B1 (ar) 2006-10-02
LV5264A3 (lv) 1993-10-10
JPH0662623B2 (ja) 1994-08-17
EP0308065A2 (en) 1989-03-22
DE3855333D1 (de) 1996-07-04
AP55A (en) 1989-09-26
HUT47935A (en) 1989-04-28
NL960001I1 (nl) 1996-03-01
DK82694A (da) 1994-07-08
NO883612L (no) 1989-02-16
JPH07113025B2 (ja) 1995-12-06

Similar Documents

Publication Publication Date Title
DK451388D0 (da) Terapeutisk nucleosider og farmaceutiske kompositioner indeholdende forbindelserne
SE8801813D0 (sv) Pharmaceutical composition
KR890701101A (ko) 제약학적 조성물
DE122004000023I2 (de) Pharmazeutische Zusammensetzung
DK330287D0 (da) Antiinflammatorisk forbindelse og farmaceutisk sammensaetning indeholdende samme
DK481989A (da) Farmaceutiske formuleringer
NZ226002A (en) Peptidylheterocyclic compounds and pharmaceutical compositions
DK191688D0 (da) Terapeutiske nucleosider
DK287188A (da) Cephalosporinforbindelser og farmaceutisk praeparat deraf
DK166279C (da) 3,4-dihydro-2h-benzooebaapyranderivater, deres fremstilling og laegemidler indeholdende disse forbindelser
DK435688A (da) Farmaceutiske midler
DK133587D0 (da) 2-heterocyclylthio-penemer, deres anvendelse og farmaceutisk komposition indeholdende forbindelserne
DK139388A (da) Farmaceutisk praeparat
DK140588A (da) Terapeutisk nucleosider
MX11584A (es) Composiciones farmaceuticas
IT1222142B (it) Composizioni farmaceutiche antivirali
DK60187D0 (da) Bis-diozopiperazin-derivater og laegemiddelformuleringer indeholdende saadanne forbindelser
DK343688A (da) Benzodipyranforbindelse og dens farmaceutiske anvendelse
IT1224244B (it) Composizione farmaceutica anoressizzante comprendente 5-idrossitrpofano
DK138888D0 (da) Farmaceutisk praeparat
IT1223086B (it) Composizione farmaceutica contenente monosialoganglioside
SE8700576D0 (sv) Pharmaceutical composition
SE8705100D0 (sv) Farmaceutisk komposition
DK681288D0 (da) Aenootropt terapeutisk laegemiddelae
DK725088A (da) Terapeutiske nucleosider

Legal Events

Date Code Title Description
B1 Patent granted (law 1993)
CTFF Application for supplementary protection certificate (spc) filed

Free format text: CA 1995 00007, 950508

CTFG Supplementary protection certificate (spc) issued

Free format text: CA 1995 00007, 950508, EXPIRES: 20091220

PUP Patent expired